Chief Scientific Officer, GreenLight Pharmaceuticals Ltd.
Dr David Gibson is a biochemist with over 15 years of experience in arthritis clinical research. He was awarded a PhD from Queen’s University Belfast in 2001 for work on drugs to reduce brain cancer spread. Dr Gibson has over 50 internationally recognised publications and has held research posts in both the USA and UK. In his role as Chief Scientific Officer he oversees research programmes to screen compounds in disease models and advances promising leads through to rigorous clinical trials. His personal research focus with GreenLight Medicines is to identify phytocannabinoids which reduce pain and inflammation in arthritis.